| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.97M | - | |
| CEO | 143.1K | $1.51M | - | |
| Other | 52.0K | $549.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2017 | Soffer Gad | EVP &Chief Strategy Officer | Sell | 6,274 | $15.47 | $97,029.08 | -1.1% | |
| Feb 9, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 13,975 | $15.46 | $216,053.50 | -3.4% | |
| Feb 9, 2017 | Turner Heather D | EVP, General Counsel &Sec. | Sell | 12,215 | $15.72 | $192,066.68 | -6.6% | |
| Feb 3, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 4,800 | $13.66 | $65,568.00 | -0.7% | |
| Jan 18, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 6,000 | $14.24 | $85,416.00 | -0.8% | |
| Jan 17, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 6,000 | $14.27 | $85,620.00 | -1.6% | |
| Jan 6, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 8,400 | $16.89 | $141,864.00 | -1.1% | |
| Dec 23, 2016 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 4,800 | $15.22 | $73,073.00 | -0.4% | |
| Dec 15, 2016 | Haqq Christopher | Chief Medical Officer | Sell | 6,000 | $15.40 | $92,400.00 | -1.6% | |
| Dec 7, 2016 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,200 | $17.93 | $129,060.00 | -0.9% |